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Human endogenous retroviruses (HERVs) are remnants of ancient infectious agents that have integrated into the
human genome. Under normal circumstances, HERVs are functionally defective or controlled by host factors. In HIV-1-
infected individuals, intracellular defense mechanisms are compromised. We hypothesized that HIV-1 infection would
remove or alter controls on HERV activity. Expression of HERV could potentially stimulate a T cell response to HERV
antigens, and in regions of HIV-1/HERV similarity, these T cells could be cross-reactive. We determined that the levels of
HERV production in HIV-1-positive individuals exceed those of HIV-1-negative controls. To investigate the impact of
HERV activity on specific immunity, we examined T cell responses to HERV peptides in 29 HIV-1-positive and 13 HIV-1-
negative study participants. We report T cell responses to peptides derived from regions of HERV detected by ELISPOT
analysis in the HIV-1-positive study participants. We show an inverse correlation between anti-HERV T cell responses
and HIV-1 plasma viral load. In HIV-1-positive individuals, we demonstrate that HERV-specific T cells are capable of
killing cells presenting their cognate peptide. These data indicate that HIV-1 infection leads to HERV expression and
stimulation of a HERV-specific CD8þT cell response. HERV-specific CD8þT cells have characteristics consistent with an
important role in the response to HIV-1 infection: a phenotype similar to that of T cells responding to an effectively
controlled virus (cytomegalovirus), an inverse correlation with HIV-1 plasma viral load, and the ability to lyse cells
presenting their target peptide. These characteristics suggest that elicitation of anti-HERV-specific immune responses is
a novel approach to immunotherapeutic vaccination. As endogenous retroviral sequences are fixed in the human
genome, they provide a stable target, and HERV-specific T cells could recognize a cell infected by any HIV-1 viral variant.
HERV-specific immunity is an important new avenue for investigation in HIV-1 pathogenesis and vaccine design.
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e165. doi:10.1371/journal.ppat.0030165
Introduction
Human endogenous retroviruses (HERV) are the remnants
of ancient infectious agents that successfully entered the
germ-line, established a truce with the host, and now make up
8.29% of the human genome [1,2]. Most HERVs are normally
quiescent, either because the sequences are truncated and
full-length transcription does not occur, or because intra-
cellular defenses such as the APOBEC3 proteins keep activity
in check [3]. However, two laboratories have recently
reconstructed infectious ‘‘hybrids’’ from one family of
endogenous retroviral sequences in the human genome,
indicating that signiﬁcant protein coding capacity and activity
potential still exist for these endogenous retroviruses [4,5].
When HIV-1 infects a permissive cell, integration occurs
within a genomic context of endogenous retroviruses. In HIV-
1-infected cells, the virus initiates numerous changes in the
cellular environment to enhance its own expression, which
also affect the endogenous retroviruses in the genome.
Intracellular defense mechanisms are compromised by pro-
teins like Vif, which works against cellular APOBEC proteins,
helping to establish a productive HIV infection [6,7]. Addi-
tionally, some HERVs have sequences that are recognized by
HIV-1 Rev, providing nuclear export for HERV transcripts in
HIV-1-infected cells [8]. RNA derived from HERVs is
detectable in the plasma of HIV-1-infected individuals [9,10].
HIV-1-infected cells are normally recognized and killed by
cytotoxic CD8þ T cells [11,12]. The proteasome collects and
degrades proteins produced within infected cells, then
human leukocyte antigen (HLA) class I molecules present
peptides on the surface of infected cells [13]. This route of
antigen presentation brings a number of antigens, both viral
and self, to the surface of infected cells. Following the
breaking of tolerance, the recognition of self antigens by
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transformation [14,15]. This suggests that HLA presentation
of HERV antigens on the surface of HIV-1-infected cells
could prime a CD8þ T cell response against HERV.
I nt h ep r e s e n ts t u d y ,w ed e t e c t e de v i d e n c eo fH E R V
production in HIV-1-positive individuals that signiﬁcantly
exceeded that in HIV-1-negative controls, in agreement with
previousstudies[9,10].OuraimwastomeasuretheCD8þTcell
response against HERV. We describe and characterize CD8þT
cell responses against HERV antigens in 29 HIV-1-positive
studyparticipantsand13HIV-1-negativeandthreehepatitisC
positive (HCVþ) controls. Finally, we discuss the implications
of these responses for the progression of HIV-1 infection.
Methods
Study Participants
Individuals were selected from participants in the UCSF
OPTIONS cohort study [16]. The study was approved by the
local institutional review board (UCSF CHR) and individuals
gave written informed consent. Peripheral blood mononu-
clear cell (PBMC) samples from HIV-1 study participants
were obtained from donated buffy coats. PBMCs from
HCVþ individuals were obtained from the University of
Toronto under their IRB. Studies were performed on
cryopreserved PBMCs.
HERV-K Expression Detection
Plasmasamples(1ml)werecentrifugedat2,000gandﬁltered
(0.2 lm) prior to RNA collection to remove remaining cellular
contaminants. High speed centrifugation (288,244g for 2 h at 4
8C in a Beckman SW41 rotor) was used to pellet particles for
RNA isolation with Trizol reagent (Invitrogen). Samples were
pre-treated with DNAse to eliminate genomic DNA contam-
ination as a source of ampliﬁed HERV sequences. Reverse
transcriptase (RT)-PCR was performed with cloned AMV RT
(Invitrogen) on samples along with control ampliﬁcations
without RT enzyme. As a calibration standard, cellular tran-
script expression of HERV and the housekeeping gene b-actin
was measured in cDNA prepared from 2.5310
6 HIV-negative
donor PBMCs. Quantiﬁcation standards were prepared by
serial dilution of the cellular cDNA. Quantitative PCR with
primers speciﬁc for the transcripts of interest was performed
onallsampleswiththeABIPrism7900HTSequenceDetection
System (Applied Biosystems) using SYBR-Green detection.
Primer sequence design and physical data were derived from
Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_
www.cgi). All ampliﬁcations were performed under the
following conditions: 94 8C (3 min); 36 cycles of 94 8C (10 s),
638C(20s),728C(25s);958C(15s),608C(15s),958C(15s).PCR
was performed using the ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems). Expression levels are
presented as percentages relative to PBMC-derived standards
and represent the means of triplicate reactions. Gel electro-
phoresisandmeltingpointanalysisofPCRproductswereused
to conﬁrm product purity and amplicon size.
Peptide Selection
Selection of candidate HERV peptides was based on
translated HERV protein sequence data compiled from the
NCBI databases, Retrosearch [17], and HERVd [18]. HIV-1
peptides were designed from the sequences of known HIV-1
epitopes listed in the Los Alamos National Laboratory HIV
immunology database [19]. Antigenic regions of HERV
insertions were assigned an HLA restriction with epitope
prediction software [20,21] or based on the HLA restriction
of corresponding regions of HIV-1 proteins.
ELISPOT Assay
ELISPOT analysis was performed as previously described
[22]. Equivalent antigen concentrations were used for HIV-1
and HERV peptides. Spot totals for duplicate wells were
averaged, and all spot numbers were normalized to numbers
of IFN-c spot-forming units (SFU) per 1 3 10
6 PBMCs. Spot
values from medium control wells were subtracted to
determine responses to each peptide.
Multicolor Cytokine Flow Cytometry
PBMCs from an HIV-1-infected individual were stimulated
with or without the peptides HIV VY10, HERV-L IQ10, or a
cytomegalovirus (CMV) pool (Becton Dickinson) for 6 h with
anti-CD28 and brefeldin A. The cells were stained with
ﬂuorophore-conjugated antibodies to CD3, CD4, CD8, CCR7,
CD27, CD28, CD45RA, interferon-c, IL-2, and TNF-a to
determine phenotype and function and an amine dye to
discriminate between live and dead cells (see also Text S1 and
Figure S1). Data were acquired with a LSR-II system (Becton
Dickinson). At least 100,000 events were collected and
analyzed with FlowJo software (TreeStar). The SPICE software
was used to assist in the organization and presentation of
multicolor ﬂow data.
51Cr Release Assays
Cryopreserved PBMCs from two study participants who
respondedtotheHERV-LIQ10peptidewerestimulatedfor7d
with peptides orpools of each antigen. Autologous, irradiated,
peptide-pulsed feeder cells were used to restimulate for an
additional7d.Cellsweretestedfortheirabilitytolysepeptide-
pulsed, autologous, Epstein-Barr virus (EBV)-transformed B
cell lines by measuring the percentage of speciﬁc
51Cr release.
Data Analysis
The Mann-Whitney and Spearman rank tests were per-
formed using GraphPad Prism version 4.00 for Windows
(GraphPad Software). p-Values less than 0.05 were considered
signiﬁcant for all tests.
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Author Summary
The human genome contains a number of remnants or fossils of
ancientviralinfectionsreferredtoashumanendogenousretroviruses
(HERV). Like fossils, these HERV are considered to be dead or inert in
most cases. However, we demonstrate that T cells in the human
immune system respond to HERV when a person is infected with the
human immunodeficiency virus (HIV). The T cells responding to HERV
share characteristics with T cells that effectively control cytomegalo-
virus,acommonchronicviralinfection.TcellsrespondingtoHERVcan
also kill target cells carrying HERV protein. For some HIV-positive
people, the strength of their response against HERV is related to
havingalowerHIVviralload.Thisstudyhasimportantimplicationsfor
new directions in HIV vaccine research. One of the key obstacles to
creating an effective HIV vaccine is overcoming the ability of some of
the viral variants produced when HIV replicates to evade the immune
responses that the body mounts to control infections. If T cells that
recognize HERV can stably target HIV-infected cells, they could be an
important factor in controlling HIV infection.Results
We quantiﬁed HERV RNA in plasma from 16 untreated
HIV-1-positive primary infection individuals and four HIV-1-
negative volunteers. We detected signiﬁcantly greater levels
of HERV transcripts in the plasma of most HIV-1-positive
individuals compared to controls (Figure 1, Mann-Whitney,
p ¼ 0.0160).
Although HIV-1 and endogenous retroviruses are phylo-
genetically distant [23], we identiﬁed several regions of
clustered and distributed amino acid identity in RT and
Gag elements. Sequence comparison within a well-conserved
protein like RT showed amino acid identities that were both
distributed and concentrated in short, contiguous regions
(Figure 2A). Although alignments of the entire amino acid
sequence were not possible with less well-conserved proteins,
short, contiguous regions of amino acid sequence identity
were still present (Figure 2B).
Because of the possibility of both a cross-reactive and
independent T cell response to HERV in HIV-1 infection, we
sought to measure the CD8þ T cell response to a number of
HERV epitopes. We manufactured peptides to test for T cell
reactivity, based upon the analysis of HERV sequence with
epitope prediction programs [20,21] and based on similarity
to known CD8þT cell epitopes in HIV-1 [19]. A subset of the
peptides shared more amino acids in common with HIV-1
( 4 amino acids), and others were unique to HERV (deﬁned
as   3 amino acids in common) (Figure 2B; Table S1). We
tested PBMCs from HIV-1-positive and -negative individuals
for HERV- and HIV-1-speciﬁc T cell responses in 29 HIV-1-
positive study participants from the OPTIONS cohort of
primary HIV-1 infection at UCSF [24] and in 13 low-risk HIV-
1-negative controls. Speciﬁc interferon-c responses were
detected to HERV peptides in HIV-1-infected individuals
but not in HIV-1-negative controls (Figure 3, Mann-Whitney,
p , 0.001). As expected, PBMCs from HIV-1-positive
Figure 1. Plasma RNA Levels of HERV-K in HIV-1-Positive and -Negative
Individuals’ Plasma
Levels of a HERV-K transcript derived from the envelope region were
measured as a percentage relative to a standard derived from peripheral
blood cells. The p-value was determined with the Mann-Whitney test.
doi:10.1371/journal.ppat.0030165.g001
Figure 2. HERV/HIV-1 Amino Acid Alignments
Alignments were anchored based on short regions of similarity identified with BLAST [38] short nearly exact match search settings, which included both
amino acid similarity estimated with evolutionary matrices (not shown in this figure) and identity.
(A) HIV-1 HXB-2 and HERV-K (gij5802821) showing a segment of the RT protein. Sequence numbering shown is based on position within individual
accessions. Identical amino acids are shown in bold.
(B) Short regions of similarity between reading frames within different HERV insertions [17,18] in the human genome and HIV-1 HXB-2 and their
correspondence to regions of HIV-1. NT is shown when the region in HIV-1 was not a known CD8þ T cell epitope and the HIV-1 peptide was not
included in the study.
doi:10.1371/journal.ppat.0030165.g002
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HERV T Cell Responsesindividuals also recognized HIV-1-speciﬁc peptides. There
was no statistical difference in the mean frequency of
responding cells speciﬁc for HERV peptides with similarity
to HIV-1 sequences and those unique to HERVs (Mann-
Whitney, p ¼ 0.1025). In addition to HIV-1-negative controls,
we also tested three HCVþ, HIV-1 negative controls. T cell
responses were not detected in response to HERV peptides in
HCVþcontrols (Figure 3). Individual T cell responses to each
peptide tested for each study participant summarized in this
ﬁgure are shown in detail in Figure S3.
In a cross-sectional analysis of the cohort of HIV-1-positive
study participants, ﬁve individuals recognized the unique
HERV peptide HERV-L IQ10 with variable magnitudes of
response (Figure 4A). In the responder with the highest T cell
response magnitude (OP562), a peptide titration assay was
performed (Figure 4B).
We measured HERV and HIV-1 T cell responses in three
study participants in longitudinal series, including OP562,
who naturally contained HIV-1 viremia without antiretroviral
therapy over the duration of our longitudinal analysis. The
unique HERV peptide HERV-L IQ10 stimulated T cell
responses in all three individuals, demonstrating persistent,
independent HERV-speciﬁc T cell responses at high magni-
tude (Figure 4C). In two of the individuals tested (OP747 and
OP841), highly active antiretroviral therapy (HAART) was
initiated, with subsequent declines in HIV-1 plasma viral load
and the level of T cell responses to the HERV-L IQ10 peptide.
We also compared responses to HIV-1 and HERV peptides
in longitudinal series with a similar pair of peptides. As the
peptides HIV Nef LG13 and HERV-H LI13 shared ﬁve amino
acids, these responses could reﬂect a level of cross-reactivity.
For OP562, responses to both HIV-1 and HERV were not
detectable by week 18, but emerged by week 63 of HIV-1
infection (Figure 4D, upper panel). Responses to the HIV Nef
LG13 and HERV-H LI13 were detected in another study
participant, OP747 (Figure 4D, lower panel).
To address potential cross-reactivity of HERV- and HIV-1-
speciﬁc T cells in other study participants, we compared
responsestoanHLA-A2-restrictedHIV-1peptideHIVRTVL9
withresponsestoaHERV-Lpeptide,HERV-LII9.TheHERV-L
II9peptideisclassiﬁedasauniqueHERVpeptideforthisstudy
because it shares only three amino acids with its closest
correspondingpeptideinHIV-1,HIVRTVL9(seeTable1).To
testtheeffectofaminoacidreplacementsintheHIV-1peptide
thatincreased theaminoacidsequencesimilaritytotheHERV
peptide, we included in this analysis a number of intermediate
sequencevariantpeptides,inwhichselectedaminoacidsinthe
HIV-1 peptide were replaced with the corresponding amino
acid from the HERV sequence (Figure 4E). One individual
(OP478) responded to the HERV peptide, but not to the HIV-1
peptide or any of the intermediate sequence variants. Two
individuals who responded to the HIV-1 peptide and the
sequencevariantpeptides(tovaryingdegrees)didnotrespond
to the HERV peptide.
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Figure 3. T Cell Responses to HERV and HIV-1 Antigens in HIV-1-Positive and -Negative Individuals Measured by Interferon-c ELISPOT
HERV peptides were grouped according to their similarity to HIV-1 peptide sequence, with ‘‘Unique HERV Peptides’’ having three or fewer amino acids in
common with an HIV-1 peptide, and ‘‘HERV Peptides Similar to HIV-1’’ having four or more peptides in common with HIV-1. Subsets of peptides were
tested in each patient, with the number tested (n¼6–23) varying depending on HLA type. Values shown for responses are normalized per peptide within
each grouping (i.e., the sum of the response values to all peptides tested divided by the number of peptides tested for each patient). The individual
peptide responses that are summarized in this figure are detailed in Figure S3. Responses in HIV-1-positive individuals are shown as closed circles and in
HIV-1-negative individuals as open circles. Responses to all HERV peptides were measured for HCVþ individuals and are shown as filled triangles.
p-Values are derived from the Mann-Whitney test.
doi:10.1371/journal.ppat.0030165.g003
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HERV T Cell ResponsesTo qualitatively compare HERV-speciﬁc CD8þ T cells with
those speciﬁc for other viruses, we determined the phenotype
and function of HIV-1-, HERV-, and CMV-speciﬁc T cells
from OP562 and OP841, who responded to the three viruses.
For this analysis, we selected HIV-1 and HERV peptides
(HERV-L IQ10 and HIV RT VY10) with only two amino acids
in common, minimizing potential cross-reactivity. Upon
stimulation with respective HERV, HIV-1, and CMV peptides,
we ascertained the phenotypes of those cells having a
cytokine production proﬁle that were associated with
degranulation (Figure 5A; Text S1). The HIV-1-speciﬁc
T cells of both study participants were skewed towards
CD45RA , whereas CD8þ T cells responding to the HERV
peptide had a greater percentage of the terminally differ-
entiated cells (CCR7 CD45RAþ) (Figure 5B, left panels). In
one study participant (OP562), HERV- and CMV-speciﬁc
populations shared a lower percentage of CD28 CD27þ
CD8þ T cells compared to their HIV-1-speciﬁc counterparts
(Figure 5B, upper right panel). In contrast, in the other study
participant (OP841), HERV- and CMV-speciﬁc populations
shared a higher percentage of CD28 CD27þ CD8þ T cells
(Figure 5B, lower right panel). Overall, the phenotype of the
HERV-speciﬁc CD8þ T cells more closely resembled the
phenotype of CMV-speciﬁc than HIV-1-speciﬁc T cells.
AsthesedatasuggestpossiblefunctionalityofHERVspeciﬁc
T cells, we measured the relationship of these responses to
HIV-1 viral load within the cohort. For the untreated time
pointsavailablefor20study participants,HERV-speciﬁc T cell
responses were signiﬁcantly inversely correlated with HIV-1
plasma viral load by Spearman non-parametric correlation
analysis and linear regression (Spearman, two-tailed, r¼ 0.49,
p¼0.03; linear regression r
2¼0.39, p¼0.003; Figure 6).
Because the ability to control viral load by eliminating
infected cells depends on killing, we measured the ability of
CD8þ T cells speciﬁc for the unique HERV peptide HERV-L
IQ10 to kill autologous B cells presenting their target peptide.
We peptide stimulated PBMCs from two individuals (OP562
and OP841) to enrich for responsive CD8þ T cells. After a
2-wk peptide stimulation, we used the
51Cr-release assay to
measure the ability of the enriched CD8þ T cells to kill
EBV-transformed B cell targets presenting cognate peptide.
CD8þ T cells enriched by stimulation with HERV peptide
were able to kill B cell targets presenting their cognate
peptide but did not lyse targets loaded with a non-cognate or
no peptide (Figure 7). Similar treatment of PBMCs from HIV-
1-negative study participants did not produce HERV-speciﬁc
effectors capable of killing peptide-pulsed targets (Figure S2).
Discussion
Upon infection of a cell, viruses like HIV-1 alter the cellular
environment to favor virus production. Viral proteins act as
chaperones to modify controls on RNA trafﬁcking into and
out of the nucleus [25,26]. Additionally, cellular suppression
mechanisms active against viral transcripts, but not acting at
the reverse transcription step, are compromised [6,7,27]. In
Figure 4. Cross-SectionalandLongitudinalELISPOTResponsestoHIV-1-andHERV-DerivedPeptidesandSequenceVariantsinHIV-1-PositiveStudyParticipants
(A) Responses in five HIV-1 positive study participants to the unique HERV peptide HERV-L IQ10.
(B) A titration of peptide concentrations for HERV-L IQ10 (open green triangles) peptides for an HIV-1-positive study participant.
(C) Responses in three individuals to a unique HERV peptide are shown as inverted green triangles. HIV-1 plasma viral loads are represented as filled red
diamonds and are determined with clinical assays for viral load (bDNA and PCR assays).
(D) Responses in two representative HIVþ study participants to an HIV-1 and HERV peptide pair with a high level of amino acid identity are shown in
blue as open and filled circles, respectively.
(E) Responses in three study participants to an HLA-A2-restricted HIV-1 epitope peptide (HIV RT VL9) and a HERV-L peptide (HERV-L II9) are shown,
along with responses to three intermediate sequence variant peptides in which selected amino acids in the HIV-1 epitope were replaced with the
equivalent amino acid found in the HERV peptide.
doi:10.1371/journal.ppat.0030165.g004
Table 1. HERV and HIV-1-Derived Peptides Tested in This Study, Divided into the Three Categories Based on Amino Acid
Sequence Identity
Unique HERV
Peptides
a
HERV Peptides with Corresponding Characterized
Epitope Peptides in HIV-1
HIV-1 Peptides
HERV-L II9 ILVHYIDDI HERV-K FD10 FEGLVDTGAD
b HIV RT VL9 VIYQYMDDL
HERV-L LY9 LQDIILVHY HERV-L KF9 KIRLPPGYF HIV Gag KK9 KIRLRPGGK HIV RT NY9 NPDIVIYQY
HERV-W DK10 DSIEGQLILK HERV-L SF9 SSGLMLMEF
b HIV RT TY9 TVLDVGDAY
HERV-L AF9 AAIDLANAF HERV-K FI8 FAFTIPAI
c HIV RT TI9 TAFTIPSI
c HIV RT VY10 VPLDEDFRKY
HERV-L IQ10 IPVHKAHKKQ HERV-H LI13 LDLLTAEKGGLCI HIV Nef LG13 LSHFLKEKGGLEG HIV RT RG10 RYQYNVLPQG
HERV-L SL10 SQGYINSPAL HERV-K VR9 VPLTKEQVR HIV RT IL9 IPLTEEAEL
HERV-L PL9 PMVSTPATL HIV Gag SL9 SLYNTVATL
HERV-K TE9 TLEPIPPGE HIV gp160 SY9 SFEPIPIHY
HERV-K FI9 FLQFKTWWI
b
HERV-K GQ9 GIPYNSQGQ
b
aUnique HERV peptides had no more than three amino acids in common with the most closely matching sequence in HIV-1. HERV peptides are shown with HIV-1 counterpart peptides
when the corresponding region of HIV-1 is a known CD8þT cell epitope (http://www.hiv.lanl.gov/content/immunology/). Additional HIV-1 peptides used in this study are also listed. We
have followed a consistent naming convention for all peptides. For HERV peptides, the name is composed of: the HERV origin (e.g., ‘‘HERV-K’’ or ‘‘HERV-L’’) followed by the single letter
codes for the starting and ending amino acid residues and finishing with the peptide length. For HIV-1, all peptide names begin with ‘‘HIV’’ followed by the protein from which the
epitope peptide is derived, followed by the single letter codes for the starting and ending amino acid residues, and finishing with the peptide length.
bPossible conservation of HLA anchor residues with the most closely matching HIV-1 peptide, but that HIV-1 peptide is not a known epitope. The sequence alignment is shown in Figure 2.
cConservation between HIV-1 and HERV peptide in HLA anchor residues [39]
doi:10.1371/journal.ppat.0030165.t001
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HERV T Cell Responsesthis altered cellular environment, HERV transcripts could
enter translational pathways from which they are normally
excluded. While only HERV-K elements contain full-length
open reading frames for all proteins, many other HERV
insertions in different families retain some form of protein-
or peptide-coding capacity relevant for producing a CD8þ T
cell response [17,28]. Even HERV elements with premature
stop codons that prevent the production of full-length
proteins could still produce peptide fragments capable of
being presented on HLA molecules, exposing the immune
system to HERV antigens.
Our study has identiﬁed T cell responses to HERV epitopes
in HIV-1-positive individuals. Five participants in the study
cohort responded in varying degrees to the unique HERV
peptide HERV-L IQ10, and in the subset of those individuals
tested longitudinally, those responses persisted over time.
This T cell response was titratable over a range of peptide
concentrations. Interestingly, the HERV-L IQ10 peptide
originates from an open reading frame in the same region
(within 31 kbp) of another HERV-L insertion containing a
polymorphism associated with improved control of HIV-1
viral load set point [29,30]. While Fellay et al. point out that
the effects of the HERV polymorphism on HIV-1 viral load
set point are not genetically distinguishable from the effects
of HLA-B*5701 in their study, they speculate about a possible
antisense mechanism of HIV-1 viral control. The authors also
point out that the HERV polymorphism results in an amino
acid substitution in one of the predicted encoded proteins.
Immunologic mechanisms of control via CD8þ Tc e l l
recognition of HERV epitopes are another plausible mech-
anism for the observed improvement of control over HIV-1
viral load set point. Both full-length, nearly intact viral
insertions such as HERV-K, but also older, more heavily
disrupted insertions, such as HERV-L, could stimulate
important HERV-speciﬁc T cell responses.
Since recognition of proteins by T cells occurs by
presentation of short peptide fragments, distantly related
viruses can still have epitopic regions in common with shared
amino acids, even in less well-conserved proteins or when
sub-full-length protein transcripts are produced by the cell.
Short regions of similarity between HERV and HIV-1 peptide
sequences could lead to a level of cross-reactivity for T cell
receptors recognizing similar epitopes. Our data demonstrate
parallel dynamics of T cell responses for peptides represent-
ing regions of similarity between HIV-1 and different HERV.
The studies described here established limits to the cross-
reactivity by demonstrating T cell responses to different
variants of HIV-1 peptide sequences that do not overlap with
T cell responses to HERV epitope peptides, but the extent
and broader implications of this potential cross reactivity
merit further study.
Having identiﬁed CD8þT cell responses to HERV epitopes
in HIV-1 infection, it was important to determine the
relevancy of these cells in the cellular immune response to
HIV-1 infection. One study participant (OP562) was able to
control HIV-1 viral load without HAART over the duration of
our longitudinal study, and he had the highest observed
magnitude of response to a unique HERV peptide. For the
entire cohort in a cross-sectional component of the study, the
level of T cell responses to HERV was inversely correlated to
HIV-1 plasma viral load. Given these data, suggestive of a role
for HERV-speciﬁc T cells in controlling HIV-1 infection, it
was important to compare the phenotype of HERV-speciﬁc T
cells to those speciﬁc for other viruses.
Previous studies of T cells in chronic viral infections of
humans have identiﬁed differences of phenotype and
function between virus-speciﬁc CD8þ T cells, which have
led to the notion that HIV-1-speciﬁc CD8þ T cells are
deﬁcient in their maturation, and potentially in function
[31,32]. We detected skewing towards CD45RA  for the HIV-
1-speciﬁc T cells in both study participants analyzed, as has
been previously observed for HIV-1 speciﬁc CD8þT cells [32].
CD8þ T cells responding to the HERV peptide had a greater
percentage of CCR7 CD45RAþ cells, presumed to be
terminally differentiated cells that are associated with
improved viral control in HIV-1-speciﬁc T cells [33]. Like
the HERV-speciﬁc CD8þ T cells, CMV-speciﬁc CD8þ T cells
in our data and in previous studies did not have a phenotypic
proﬁle skewed towards CD45RA  [33]. Additionally, HERV-
speciﬁc CD8þT cells had a lower percentage of CD28 CD27þ
CD8þ T cells compared to their HIV-1-speciﬁc counterparts
in one study participant, as reported in previous studies [31].
In the other study participant, both HERV- and CMV-speciﬁc
Figure 5. Phenotypic Profile Comparison of HIV-1-, HERV-, and CMV-Specific T Cells Measured by Multicolor Cytokine Flow Cytometry
(A) Phenotypic characterization of cytokine producing cells (see Text S1) from two HIV-1-positive study participants for the markers CCR7, CD27, CD28,
and CD45RA are shown as pie charts. The colors in the pie charts correspond to the phenotypic categories delineated in the table below them.
(B) A subset of the data from (A) is shown, highlighting comparisons of specific phenotypes. The percentages of CD45RAþ (unfilled bars) and
CD45RA  (filled bars) T cells are shown in the panels in the left column. The panels in the right column detail the percentages of CD28  T cells from
the two study participants.
doi:10.1371/journal.ppat.0030165.g005
Figure 6. Inverse Correlation between Anti-HERV T Cell Responses and
HIV-1 Plasma Viral Load
PBMCsfrom20HIV-1-positiveindividualsnotontreatmentwereanalyzedby
ELISPOT for HERV responses. The mean response (.50 SFU/million PBMCs)
values for all HERV peptides tested had a significant inverse correlation to
HIV-1 plasma viral load (Spearman, two-tailed, r ¼  0.49, p ¼ 0.03) and by
linear regression (r
2¼0.39, p¼0.003) as shown in the figure.
doi:10.1371/journal.ppat.0030165.g006
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CD8þ T cells compared to their HIV-1-speciﬁc counterparts.
CD28 expression on the cell surface modulates responsive-
ness to co-stimulation, and can change according to the
activation level of a T cell [34]. Higher levels of CD28 on the T
cell surface increase the sensitivity of that T cell to B7 co-
stimulation by antigen presenting cells, but engagement of
the CD28 receptor leads to its down-regulation in a negative
feedback loop [35]. Overall, our data are consistent with
previous phenotypic and functional observations for HIV-1-
speciﬁc CD8þ T cells, and indicate that HERV-speciﬁc CD8þ
T cells more closely resemble CD8þ T cells induced in
controlled chronic viral infections such as CMV.
Controlling HIV-1 viral load also requires killing of infected
target cells. HERV antigen production by HIV-1-infected cells
would make them a potential target for HERV-speciﬁc CD8þ
T cells. However, as HERV-speciﬁc CD8þ T cells are speciﬁc
for self-antigens, CD8þ cells responding to HERV peptides
may be impaired in their ability to kill targets. Our data show
that HERV-speciﬁc CD8þT cells speciﬁcally kill B cell targets
presenting HERV peptides. Cells capable of killing B cell
targets presenting HERV peptides were not detectable in the
PBMCs of HIV-1-negative study participants.
The T cell responses against HERV peptides in HIV-1-
positive individuals appear to be driven by HIV-1. With
effective HIV-1 suppression by HAART, responses to unique
HERV peptides and those similar to HIV-1 both undergo a
decline. However, chronic viral infections can lead to
dysregulation of the CD8þ T cell response [36]. To rule out
the effects of chronic viral infection in generating HERV
CD8þ T cell responses, we analyzed responses in HCVþ
controls. The lack of HERV-speciﬁc T cell responses in HCVþ
study participants indicates that HERV-speciﬁc CD8þ T cell
responses are present in HIV-1 but not other chronic viral
infections such as HCV.
Our data have important implications for redeﬁning the
breadth of epitopes that make up what is considered the
‘‘HIV-1-speciﬁc’’ CD8þT cell response. CD8þT cell depletion
in rhesus macaques has been used to demonstrate the
importance of CD8þT cells in viral control [37]. Of necessity,
the depletion was performed regardless of speciﬁcity of the
CD8þ T cells. Thus, CD8þ T cells with speciﬁcities for
epitopes other than those derived from the virus itself could
have also been depleted in these experiments and be
important for viral control. Our results demonstrate HERV-
speciﬁc T cell responses in individuals with primary HIV-1
infection. While these responses could play a role in HIV-1
pathogenesis by attacking any cell presenting HERV epitopes,
it is interesting to consider the potential beneﬁt of these
responses to the control of HIV-1. An inverse correlation
between anti-HERV T cell responses and HIV-1 plasma viral
load demonstrates a role for HERV CD8þ T cell responses in
helping to contain HIV-1 viremia. Additionally, the pheno-
type of HERV-speciﬁc CD8þ T cells more closely resembles
that of CD8þ T cells generated in the setting of a viral
infection with good immunologic control. Our results suggest
that HERV-speciﬁc CD8þ T cells, both those cross-reactive
with HIV-1 epitopes and those speciﬁc for their HERV
targets, should be included in the repertoire of cells capable
of controlling HIV-1 replication. Because one of the greatest
challenges for the immune system in effectively and durably
controlling retroviral replication is responding to rapidly
arising viral variants, it is interesting to speculate on the
potential of HERV immunity to aid in broad spectrum and
long-term immune control of HIV-1. HERVs are genome-
encoded elements with the same sequences present in every
cell. An anti-HERV-speciﬁc immune response could target
any HIV-1-infected cell irrespective of HIV-1 viral sequence.
HERV could provide an effective surrogate target for the
immune response to eliminate HIV-1-infected cells and bears
investigation as candidates for inclusion in a new type of
HIV-1 vaccine. In summary, we show HERV-speciﬁc immune
responses in HIV-1 infection. Manipulation of these re-
sponses could play an important role in HIV-1 immunother-
apeutics, or augment HIV-1 vaccine strategies.
Figure 7. HERV-Specific T Cells Lyse HERV Peptide-Pulsed Targets
HERV-L IQ10-specific T cells were tested against autologous B cells
pulsed with HERV-L IQ10 peptide (open inverted green triangles), control
peptide (filled squares), or no peptide (open squares) in independent
peptide-stimulated expansions from two HIV-positive study participants.
doi:10.1371/journal.ppat.0030165.g007
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Figure S1. Gating Strategy for Multicolor Cytokine Flow Cytometry
Found at doi:10.1371/journal.ppat.0030165.sg001 (328 KB PDF).
Figure S2. CD8þ T Cell Peptide Expansions from HIV-1-Negative
Study Participants
Found at doi:10.1371/journal.ppat.0030165.sg002 (180 KB PDF).
Figure S3. Supplement to Figure 3
Detailed responses to all peptides tested on all individuals summar-
ized in Figure 3 of the text.
Found at doi:10.1371/journal.ppat.0030165.sg003 (385 KB PDF).
Table S1. Additional Peptide Data Including HERV Subtypes
with Accession Numbers and HIV HXB-2 Protein Location and
HLA Restrictions
Found at doi:10.1371/journal.ppat.0030165.st001 (67 KB DOC).
Table S2. Primer Sequences for HERV Ampliﬁcation (Table S2a) and
Sequences Obtained from HERV-K Env Ampliﬁcation (Table S2b)
Found at doi:10.1371/journal.ppat.0030165.st002 (33 KB DOC).
Text S1. Supplemental Methods
Found at doi:10.1371/journal.ppat.0030165.sd001 (26 KB DOC).
Accession Numbers
HERV-L ORF accession numbers from Retrosearch [17] are 162563,
162568, 162604, 162605, and 162613. The National Center for
Biotechnology Information (http://www.ncbi.nlm.nih.gov/) accession
numbers for the proteins discussed in this paper are HERV-H
(gij44887889); HERV-K (gij52001472, gij5802821, gij75766508,
gij67782351); and HERV-W (gij52000737).
Acknowledgments
We thank Kyryl Zagorovsky for assistance with the primer and HERV
family sequence alignments. We would also like to thank Mario
Roederer, National Institutes of Health, for the use of the SPICE
softwareprogram.WewouldliketothankJ.‘‘Mike’’ McCuneforcritical
reading of this manuscript and John Carroll for graphics assistance.
Author contributions. KEG, RBJ, MAO, and DFN composed the
manuscript and planned the experimentation for this work. RBJ
designed, validated, and performed the quantitative PCR experi-
ments with the assistance of NA. KEG, NA, DAM, and RBJ, JMC, and
DFN performed the ELISPOT analysis of T cell responses. ALE
performed the
51Cr-release assays. AA performed the initial database
searches to identify peptide sequences, with KEG, AA, FMH, and DFN
developing the selection process for the peptides. KEG and LCN
performed the multicolor ﬂow cytometry experiments. FMH directs
the OPTIONS cohort, with GS as data manager, which provided
samples for the study. SRN and JL were important early contributors
to the initial selection of HERV insertions on which to focus further
experimentation. MAO and DFN are equal last authors.
Funding. This work was supported by funds from the J. David
Gladstone Institutes, the UCSF AIDS Research Institute, and the
Irvington Institute (LCN). DFN and MAO receive funds from Pﬁzer
under a sponsored research agreement.
Competing interests. KEG, RBJ, DAM, AA, FMH, SRN, JL, MAO,
and DFN are named as inventors on a patent application, based on
this work, which was ﬁled by their respective institutions.
References
1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial
sequencing and analysis of the human genome. Nature 409: 860–921.
2. Bannert N, Kurth R (2004) Retroelements and the human genome: new
perspectives on an old relation. Proc Natl Acad Sci U S A 101 Suppl 2:
14572–14579.
3. Esnault C, Millet J, Schwartz O, Heidmann T (2006) Dual inhibitory effects
of APOBEC family proteins on retrotransposition of mammalian endog-
enous retroviruses. Nucl Acids Res 34: 1522–1531.
4. Dewannieux M, Harper F, Richaud A, Letzelter C, Ribet D, et al. (2006)
Identiﬁcation of an infectious progenitor for the multiple-copy HERV-K
human endogenous retroelements. Genome Res 16: 1548–1556.
5. Lee YN, Bieniasz PD (2007) Reconstitution of an infectious human
endogenousretrovirus.PLoSPathog3:e10.doi:10.1371/journal.ppat.0030010
6. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme
APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Nat Med 9: 1404–1407.
7. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks
the antiviral activity of APOBEC3G by impairing both its translation and
intracellular stability. Molecular Cell 12: 591–601.
8. Yang J, Bogerd HP, Peng S, Wiegand H, Truant R, et al. (1999) An ancient
family of human endogenous retroviruses encodes a functional homolog of
the HIV-1 Rev protein. Proc Natl Acad Sci U S A 96: 13404–13408.
9. Contreras-Galindo R, Gonzalez M, Almodovar-Camacho S, Gonzalez-
Ramirez S, Lorenzo E, et al. (2006) A new Real-Time-RT-PCR for
quantitation of human endogenous retroviruses type K (HERV-K) RNA
load in plasma samples: increased HERV-K RNA titers in HIV-1 patients
with HAART non-suppressive regimens. J Virol Methods 136: 51–57.
10. Contreras-Galindo R, Kaplan MH, Markovitz DM, Lorenzo E, Yamamura Y
(2006) Detection of HERV-K(HML-2) viral RNA in plasma of HIV type 1-
infected individuals. AIDS Res Hum Retroviruses 22: 979–984.
11. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, et al. (1988) HIV-1
gag-speciﬁc cytotoxic T lymphocytes deﬁned with recombinant vaccinia
virus and synthetic peptides. Nature 336: 484–487.
12. Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, et al. (1987) HIV-
speciﬁc cytotoxic T lymphocytes in seropositive individuals. Nature 328:
345–348.
13. Pamer E, Cresswell P (1998) Mechanisms of MHC class I-restricted antigen
processing. Ann Rev Immunol 16: 323–358.
14. Rakoff-Nahoum S, Kuebler PJ, Heymann JJ, Sheehy ME, Ortiz GM, et al.
(2006) Detection of T lymphocytes speciﬁc for human endogenous
retrovirus K (HERV-K) in patients with seminoma. AIDS Res Hum
Retroviruses 22: 52–56.
15. Schiavetti F, Thonnard J, Colau D, Boon T, Coulie PG (2002) A human
endogenous retroviral sequence encoding an antigen recognized on
melanoma by cytolytic T lymphocytes. Cancer Res 62: 5510–5516.
16. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, et al. (2002) Use of
laboratory tests and clinical symptoms for identiﬁcation of primary HIV
infection. AIDS 16: 1119–1129.
17. VillesenP,AagaardL,WiufC,PedersenFS(2004)Identiﬁcationofendogenous
retroviral reading frames in the human genome. Retrovirology 1: 32.
18. Paces J, Pavlicek A, Zika R, Kapitonov VV, Jurka J, et al. (2004) HERVd: the
HumanEndogenousRetroVirusesDatabase:update.NucleicAcidsRes32:D50.
19. Bette TM, Korber CB, Haynes BF, Koup R, Moore JP, et al. (2005) HIV
molecular immunology 2005. Los Alamos (New Mexico): Los Alamos
National Laboratory, Theoretical Biology and Biophysics. LA-UR 06–0036.
20. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S (1999)
SYFPEITHI: database for MHC ligands and peptide motifs. Immunoge-
netics 50: 213–219.
21. Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential
HLA-A2 binding peptides based on independent binding of individual
peptide side-chains. J Immunol 152: 163–175.
22. Meiklejohn DA, Karlsson RK, Karlsson AC, Chapman JM, Nixon DF, et al.
(2004) ELISPOT cell rescue. J Immunol Methods 288: 135–147.
23. Cofﬁn JM, Hughes SH, Varmus HE, editors (1997) Retroviruses. Cold
Spring Harbor (New York): Cold Spring Harbor Laboratory Press.
24. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF (2004) Human
CD4þ CD25þ regulatory T cells control T-cell responses to human
immunodeﬁciencyvirusandcytomegalovirusantigens.JVirol78:2454–2459.
25. Richard N, Iacampo S, Cochrane A (1994) HIV-1 Rev is capable of shuttling
between the nucleus and cytoplasm. Virology 204: 123–131.
26. Meyer BE, Malim MH (1994) The HIV-1 Rev trans-activator shuttles
between the nucleus and the cytoplasm. Genes Dev 8: 1538–1547.
27. Newman ENC, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005)
Antiviral function of APOBEC3G can be dissociated from cytidine
deaminase activity. Current Biology 15: 166–170.
28. Barbulescu M, Turner G, Seaman MI, Deinard AS, Kidd KK, et al. (1999)
Many human endogenous retrovirus K (HERV-K) proviruses are unique to
humans. Curr Biol 9: 861–868.
29. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, et al. (2007)
A whole-genome association study of major determinants for host control
of HIV-1. Science: 1143767.
30. Kulski JK, Dawkins RL (1999) The P5 multicopy gene family in the MHC is
related in sequence to human endogenous retroviruses HERV-L and
HERV-16. Immunogenetics 49: 404–412.
31. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GMA, et al. (2002)
Memory CD8þ T cells vary in differentiation phenotype in different
persistent virus infections. Nat Med 8: 379–385.
32. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, et al. (2001)
Skewed maturation of memory HIV-speciﬁc CD8 T lymphocytes. Nature
410: 106–111.
33. Northﬁeld JW, Loo CP, Barbour JD, Spotts G, Hecht FM, et al. (2007)
HIV-1-speciﬁc CD8þ TEMRA cells in early infection are linked to control
of HIV-1 viremia and predict the subsequent viral load set point. J Virol 81:
5759–5765.
34. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell co-
stimulation. Annu Rev Immunol 14: 233–258.
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e165 1626
HERV T Cell Responses35. Linsley PS, Bradshaw J, Urnes M, Grosmaire L, Ledbetter JA (1993) CD28
engagement by B7/BB-1 induces transient down-regulation of CD28
synthesis and prolonged unresponsiveness to CD28 signaling. J Immunol
150: 3161–3169.
36. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJD, Suresh M, et al.
(1998) Viral immune evasion due to persistence of activated T cells without
effector function. J Exp Med 188: 2205–2213.
37. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, et al. (1999) Dramatic rise
in plasma viremia after CD8þT cell depletion in simian immunodeﬁciency
virus-infected macaques. J Exp Med 189: 991–998.
38. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997)
Gapped BLAST and PSI-BLAST: a new generation of protein database
search programs. Nucleic Acids Res 25: 3389–3402.
39. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, et al. (2000)
Nonstandard peptide binding revealed by crystal structures of HLA-B*5101
complexedwithHIVimmunodominantepitopes.JImmunol165:3260–3267.
PLoS Pathogens | www.plospathogens.org November 2007 | Volume 3 | Issue 11 | e165 1627
HERV T Cell Responses